OTCMKTS:MLLCF Molecular Partners (MLLCF) Stock Price, News & Analysis $4.22 0.00 (0.00%) As of 09/5/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Molecular Partners Stock (OTCMKTS:MLLCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Molecular Partners alerts:Sign Up Key Stats Today's Range$4.22▼$4.2250-Day Range$4.22▼$4.2252-Week Range$3.66▼$10.14VolumeN/AAverage Volume525 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Read More Receive MLLCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLLCF Stock News HeadlinesMolecular Partners price target lowered to $4 from $4.50 at JPMorganSeptember 3 at 1:00 PM | msn.comMolecular Partners AG Reports H1 2025 ProgressAugust 25, 2025 | tipranks.comWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.September 6 at 2:00 AM | SmartAsset (Ad)Molecular Partners Advances Clinical Programs and Strengthens Financial Position in H1 2025August 25, 2025 | msn.comMolecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeuticsAugust 21, 2025 | finance.yahoo.comMolecular Partners AG Appoints Martin Steegmaier, Ph.D. as Chief Scientific OfficerAugust 21, 2025 | quiverquant.comQMolecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade)May 13, 2025 | seekingalpha.comUsing advances in AI to combat illegal timber tradeNovember 1, 2024 | washingtonpost.comSee More Headlines MLLCF Stock Analysis - Frequently Asked Questions How have MLLCF shares performed this year? Molecular Partners' stock was trading at $4.11 at the start of the year. Since then, MLLCF shares have increased by 2.7% and is now trading at $4.22. How do I buy shares of Molecular Partners? Shares of MLLCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MLLCF CIKN/A Webwww.molecularpartners.com Phone(144) 755-7700FaxN/AEmployees167Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:MLLCF) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.